Valion Bio advances oral mucosal Entolimod formulation program for acute radiation syndrome

PUBT · 1d ago
Valion Bio advances oral mucosal Entolimod formulation program for acute radiation syndrome
  • Valion Bio announced completion of formulation work for an oral mucosal version of investigational radiation drug Entolimod using SKL’s BioViscid platform.
  • No clinical trial launch or human study readout was disclosed; results were not presented, with future development implied but not dated.
  • The program targets a needle-free option intended to support rapid, large-scale deployment for acute radiation syndrome preparedness.
  • Rationale cited prior animal research on injected Entolimod suggesting protective effects before exposure, improved survival when given after exposure.
  • Strategy keeps injectable development in parallel, positioning oral mucosal dosing as an additional pathway for stockpiling, distribution, administration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610090745ACCESSWRNAPR_____1234949) on October 09, 2026, and is solely responsible for the information contained therein.